Keyword: University of Oxford
OVM will use the $12.5 million investment to take vaccines against cervical cancer and other solid tumors into the clinic.
European researchers discovered how drugs bind to the enzyme DHODH, which could lead to more selective cancer drugs.
Nightstar will complete a phase 3 trial of its choroideremia gene therapy and advance two other eye disease candidates through early-stage studies.
Takeda Pharmaceutical has teamed up with Harrington Discovery Institute to support research into treatments for rare diseases.
In this week's EuroBiotech Report, Europe-wide scrap for EMA intensifies, Vifor goes solo post-IPO, Mission bags Fox funding and more.
Mission Therapeutics and the University of Oxford have landed a Michael J. Fox Foundation grant to fund testing of USP30 inhibitors.
Novo Nordisk has committed £115 million ($144 million) to set up a Type 2 diabetes drug discovery center at the University of Oxford.
OxSonics and its sister company have raised $11 million to take ultrasound-based technologies into clinical development.
Evotec and the University of Oxford have teamed up to bridge the gap between academic research and industry.
Our EuroBiotech roundup this week features a pair of IPOs, the takeover of Alizé Pharma II and advance of Galapagos' CF pipeline.